NCT01841281View on ClinicalTrials.gov

L-arginine in Severe Asthma Patients Grouped by Exhaled Nitric Oxide Levels

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

August 31, 2018

Study Completion Date

December 31, 2019

Conditions
AsthmaInflammation
Interventions
DRUG

L-Arginine

L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.

DRUG

Placebo

Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients.

Trial Locations (1)

95817

UC Davis CTSC Clinical Research Center, Sacramento

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Nicholas Kenyon

OTHER

NCT01841281 - L-arginine in Severe Asthma Patients Grouped by Exhaled Nitric Oxide Levels | Biotech Hunter | Biotech Hunter